Additional Relevant Details enrolled the first patient in the STRIDE-1 (Symptom Treatment in Resistant Depression 1) study, a Phase 3 trial evaluating the efficacy and safety of AXS-05 for the treatment of treatment resistant depression (TRD). AXS-05 is an innovative oral therapeutic, with activity at several key neurotransmitter systems, being developed for the treatment of CNS disorders. AXS-05 combines mechanisms of action of several distinct antidepressant drug classes.